Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Antimicrobial resistance

Indicators developed to measure EU progress on tackling antibiotic resistance

The indicators cover antibiotic consumption and antimicrobial resistance in the community, in hospitals and in food-producing animals.

Antimicrobial resistance E Coli

Source: Shutterstock.com

The outcome indicators cover antibiotic consumption and resistance for both humans and animals. For monitoring antibiotic resistance, the joint scientific opinion recommends the primary indicator to be the proportion of methicillin-resistant Staphylococcus aureus (MRSA) and third generation cephalosporin-resistant Escherichia coli

A set of outcome indicators has been developed to help EU member states monitor their progress in combatting antimicrobial resistance[1].

The indicators, which are the result of collaboration between the European Food Safety Authority, European Medicines Agency and European Centre for Disease Prevention and Control, cover antibiotic consumption and resistance for both humans and animals. The indicators are divided into primary and secondary categories. Primary indicators broadly reflect the situation around antimicrobial consumption and resistance, and secondary indicators have been designed to provide information on more specific issues.

For human antibiotic use, the primary recommended indicator is total consumption of antibacterial medicines for systemic use — in hospitals and the community — measured by defined daily doses per 1,000 inhabitants and per day.

The first secondary indicator is the ratio of use of broad-spectrum penicillins, cephalosporins, macrolides and fluoroquinolones to use of narrow-spectrum penicillins, cephalosporins and erythromycin, in the community. The second is the proportion of total hospital consumption of glycopeptides, third and fourth generation cephalosporins, monobactams, carbapenems, fluoroquinolones, polymyxins, piperacillin and enzyme inhibitor, linezolid, tedizolid and daptomycin.

For monitoring antibiotic resistance, the joint scientific opinion recommends the primary indicator to be the proportion of methicillin-resistant Staphylococcus aureus (MRSA) and third generation cephalosporin-resistant Escherichia coli — both pathogens are described as being of ‘major public health importance’.

The first secondary indicator is the proportion of Klebsiella pneumoniae with combined resistance to aminoglycosides, fluoroquinolones and third-generation cephalosporins. The second is the proportion of penicillin-resistant and macrolide-resistant Streptococcus pneumoniae, to cover issues seen in both hospital and the community.

Data on the proportion of the emerging threat of carbapenem-resistant K. pneumoniae, should also be used to monitor efforts to tackle resistance, the recommendations state.

Other recommendations cover antibiotics used in food–producing animals including the proportion of E. coli bacteria from food-producing animals that are susceptible or resistant to a number of antimicrobials.

Vytenis Andriukaitis, the European commissioner for health and food safety, said that back in June 2017, when he presented the new EU Action plan on antimicrobial resistance, he had promised that they would define how progress would be measured.

“Without these indicators, we would not be able to assess our progress in tackling the serious health threat posed by [antimicrobial resistance].

“The indicators, presented in the form of a scientific opinion, are the result of close cooperation between the three EU agencies, each drawing on their specific expertise and data from monitoring of antimicrobial resistance and antimicrobial consumption in animals and humans,” he added.

Figures released in October 2017 show sales of antibiotics for use in animals in the UK have fallen to their lowest level since records began, exceeding a government target two years early.

It is estimated that antimicrobial resistance accounts for over 25,000 deaths per year in the EU and over 1.5 billion euros in healthcare costs and loss of productivity.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203827

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Zoonoses

    Zoonoses

    An accessible textbook covering zoonotic diseases, which affect humans but are contracted from animals.

    £47.00Buy now
  • Hospital Pharmacy

    Hospital Pharmacy

    Covers pharmacy practice in hospitals, and discusses the range of services provided.

    £34.00Buy now
  • MCQs in Pharmaceutical Science and Technology

    MCQs in Pharmaceutical Science and Technology

    MCQs in Pharmaceutical Science and Technology includes 600 MCQs progressing from basic science through to clinical considerations.

    £32.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £32.00Buy now
  • Hospital Pre-registration Pharmacist Training

    Hospital Pre-registration Pharmacist Training

    A practical explanation for undergraduates and pre-registration trainees. Shows what to expect from a hospital pre-registration pharmacist training programme.

    £24.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £52.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Antimicrobial resistance E Coli

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.